Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Christine Brown
Beckman Research Institute/city of Hope, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Mustang Bio., Inc.
Equity Interest - Publicly traded entity (e.g., stock, stock option, or other ownership interest)
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a broad range of proprietary chimeric antigen receptor engineered T cell (CAR T) immunotherapies and gene therapies in areas of unmet need. Mustang aims to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, to fund research and development, and to outlicense or bring the technologies to market. Mustang has partnered with top medical institutions to advance the development of CAR T and CRISPR/Cas9-enhanced CAR T therapies across multiple cancers, as well as lentiviral gene therapy for X-SCID. Dr. Brown is a Co-Principal Investigator on the funded research grant that proposes to improve outcomes for patients with malignant glioma by enhancing IL13BBζ Chimeric Antigen Receptor T Cell therapy through combination with anti-PD-1 checkpoint blockade. Given that the project aims of the grant, in part, are to evaluate IL13Rα2- Chimeric Antigen Receptor T Cell therapy in combination with nivolumab in patients with recurrent malignant glioma and that the NIH-funded trial results could affect Dr. Brown’s Mustang-related interests, the interests were determined to be related.
Clinical evaluation of IL13Ra2-targeted CAR T cell therapy in combination with nivolumab in patients with recurrent malignant glioma
NARRATIVE We propose to evaluate a combination therapy to enhance the effectiveness of chimeric antigen receptor (CAR) T cells for malignant glioma (MG) by relieving tumor-induced immune suppression using the anti-PD-1 antibody nivolumab. We anticipate that CAR T cells will directly target antigen-positive glioma cells and that anti-PD1 will augment endogenous and CAR T cell responses. The proposed studies aim to improve our understanding of the glioma microenvironment and identify key drivers of response or resistance to combining CAR T and anti- PD-1 immunotherapies.
Filed on April 29, 2019.
Tell us what you know about Christine Brown's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Christine Brown filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Christine Brown | Beckman Research Institute/city of Hope | Conflict of Interest | Mustang Bio., Inc. | $80,000 - $99,999 |
| Christine Brown | Beckman Research Institute/city of Hope | Conflict of Interest | Mustang Bio., Inc. | $60,000 - $79,999 |
| Christine Brown | Beckman Research Institute/city of Hope | Conflict of Interest | Mustang Therapeutics | $60,000 - $79,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.